Format

Send to

Choose Destination
Future Oncol. 2015;11(5):747-57. doi: 10.2217/fon.14.313.

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.

Author information

1
University of Oklahoma Health Sciences Center, Stephenson Oklahoma Cancer Center, 800 NE 10th Street, Suite 5040, Oklahoma City, OK 73104, USA.

Abstract

Olaparib (Lynparzaâ„¢; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. It has been tested in Phase I and II trials and has single-agent activity in both germline BRCA mutated and sporadic ovarian cancer. Phase III trials assessing the efficacy of olaparib in the maintenance setting following first line and platinum-sensitive recurrence are underway for patients with a germline BRCA mutation, given the inherent molecular compatibility with the drug's mechanism of action.

KEYWORDS:

BRCA mutation; PARP inhibitor; homologous recombination pathway; olaparib; ovarian cancer

PMID:
25757679
DOI:
10.2217/fon.14.313
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center